Search

MPS VI Clinical Trials

Mucopolysaccharidosis VI (MPS VI), also known as Maroteaux-Lamy Syndrome, is an inherited lysosomal storage disorder caused by the deficiency of an enzyme normally required for the breakdown of certain complex carbohydrates.

Learn about our MPS VI clinical trials below.

Galsulfase

Studies

Study MPSVI CSP Complete

Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

view study

Indication

Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)

Goal

The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term galsulfase treatment; to further characterize the long-term safety of galsulfase treatment.

Investigational therapeutic

Galsulfase

Status

This study has been completed

Study Type

Phase 4